News

The PDUFA target date is set for March 31, 2023.

The chief medical officer of Triumvira Immunologics discussed the company’s future plans.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

All 5 patients on ERT at study start have since been able to withdraw after gene therapy treatment.

Both botaretigene sparoparvovec and JNJ-81201887 were well-tolerated in treated patients, according to data from the 2022 AAO meeting.

The professor of genetics at Federal University of Rio Grande do Sul discussed how RGX-121 has the potential to change the treatment landscape of MPSII.

ORR was 80% in the first cohort of phase 1b at the recommended phase 2 dose.

A retrospective study measured correlations of ICANS and NfL in patients with a history of diffuse large B-cell lymphoma.

The director of the Regenerative Medicine Institute at Cedars Sinai discussed results from a phase 1/2a study of CNS10-NPC-GDNF.

Lyell will soon initiate a phase 1 trial of LYL845 with initial data expected in 2024.

Review top news and interview highlights from the week ending October 7, 2022.

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.

The new, 2-year data is from a roll-in cohort of 10 patients presented at the HFSA 2022 meeting.

Karen Walker, chief technology officer, Kyverna Therapeutics, discussed the company’s CAR T-cell and regulatory T-cell technologies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Five patients with lupus treated with anti-CD19 CAR T-cell therapy are now in remission.

Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.

The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.

Rocket Pharma presented updated data from adult and pediatric patients at the 2022 HFSA meeting.

The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.

Solid has also pivoted from developing SGT-001 to SGT-003 for treating Duchene muscular dystrophy.

Participants in the AAVIATE trial had up to an 85% decrease in treatment burden 6 months after treatment with RGX-314.

Newborn Cell Therapies Group at Monash University has received a $50,000 grant from Lions Cord Blood foundation.

Disease-free survival was 56% in 105 participants over 3 years.

Review top news and interview highlights from the week ending September 30, 2022.

Patients treated with the highest dose of MIC-Lx had lymphocyte reactivity against third-party cells but not stimulatory donor blood cells.

Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.